Safety, tolerability, pharmacokinetics, and antitumor activity of SHR-A1811 (a HER2-targeting ADC) in HER2-expressing/mutated advanced solid tumors: a global phase 1, multi-center, first-in-human study

Research output: Contribution to conferencePaperpeer-review

Original languageEnglish
Publication statusPublished - 18 Apr 2023
EventAmerican Association for Cancer Research -
Duration: 14 Apr 202320 Apr 2023


ConferenceAmerican Association for Cancer Research

Cite this